EUVIMEDEUVIMED entdecken
Crossref

BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026

Yuping Si, Changnian Li, Li Hou

Clinical Lymphoma Myeloma and Leukemia · 2026-10

DOI: 10.1016/j.clml.2026.10.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Yuping Si und 2 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Si, Y., Li, C., & Hou, L. (2026). BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.024

Vancouver

Si Y, Li C, Hou L. BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.024

BibTeX
@article{Si2026,
  author = {Si, Yuping and Li, Changnian and Hou, Li},
  title = {BCMA-directed antibodies in multiple myeloma: new agents and treatment strategies from IMS 2026},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.024}
}
Kostenlos starten →